Cabozantinib: A Review in Advanced Hepatocellular Carcinoma

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond

(2018) Jean-Luc Raoul et al.   CANCER TREATMENT REVIEWS

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma

(2018) Masatoshi Kudo   Liver Cancer

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

(2018) Lorenza Rimassa et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

(2018) Robin Kate Kelley et al.   JOURNAL OF CLINICAL ONCOLOGY

Second-line Treatments of Advanced Hepatocellular Carcinoma

(2018) Ziad Bakouny et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

(2017) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults

(2016) Linh Nguyen et al.   ANTI-CANCER DRUGS

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

(2016) Linh Nguyen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma

(2016) Jian Liu et al.   PLoS One

Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects

(2015) Linh Nguyen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

(2015) Linh Nguyen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

(2015) L Zhou et al.   ONCOGENE

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

(2014) Q. Xiang et al.   CLINICAL CANCER RESEARCH

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH